The market for government-approved medication targeting long-term weight reduction and maintenance is expanding. On Wednesday, the U.S. Food and Drug Administration approved Zepbound, which is made by Eli Lilly and Company and intended for use by adults with obesity or those suffering from a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. The medication, which is intended to be combined with a reduced-calorie diet and increased physical activity, is expected to available by the end of the year.

Tirzepatide, the active ingredient in Zepbound for weight loss, is already approved under the trade name Mounjaro for use along with diet and exercise to help improve glucose levels in adults with type 2 diabetes mellitus.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Employee Participation
Employee-Paid
Employer-Paid